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Aim: The aim of our study is to investigate the disorders of ferritin functioning in breast cancer (BC) cells of different molecular sub-
type. Materials and Methods: The cell lines used in the analysis include T47D, MCF-7, MDA-MB-231, MDA-MB-468, MCF-10A, 
and 184A1. Ferritin heavy chains (FTH) expression was studied by immunohistochemical method. “Free iron” content and superox-
ide dismutase (SOD) activity were determined by means of EPR spectroscopy. Reactive oxygen species (ROS) level and peculiarities 
of microRNA expression in studied cell lines were evaluated using flow cytometry and PCR analysis, respectively. Results: It has been 
demonstrated that FTH expression directly correlates with proliferative activity of cells of both luminal (r = 0.51) and basal subtypes 
(r = 0.25), inversely correlates with expression of steroid hormones in cells of basal subtype (ER: r = −0.46; PR: r = −0.44) and does 
not depend on tumorigenic activity of both subtypes of studied cells (r = 0.12 and r = 0.9). Obtained data are the evidence that cells 
of luminal subtype B (MCF-7 cell line) and basal subtype (MDA-MB-231 and MDA-MB-468 cell lines) with high proliferative 
activity contain the highest level of free iron (2.9 ± 0.19·1016
 
and 3.0 ± 0.22·1016) that can be consequence of intensive use of this 
element by cells, which actively divide and grow. Along with it, in cell of lines of basal subtype MDA-MB-231 and MDA-MB-468, 
high level of FTH (254 ± 2.3 and 270 ± 1.9) is being detected in consequence of increase of level of free iron, ROS (11.3 ± 1.05 and 
7.27 ± 0.26) and SOD (9.4 ± 0.24 and 8.5 ± 0.18) as well as decrease of expression of microRNA 200b. In contrast, cells of luminal 
subtype B of MCF-7 line were distinguished by high expression of microRNA 200b and low ferritin level (125 ± 2.7). Conclusion: 
Obtained data demonstrate that tumor cells, which are referred to different molecular subtypes, are characterized by changes in sys-
tem of support of balance of intercellular iron and certain associations of studied factors.
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Breast cancer (BC) occupies the first place 
in cancer-related morbidity among female population 
in Ukraine [1]. In recent years, prognosis of BC clini-
cal course is based on determination of its molecular 
subtypes namely, luminal A, luminal B, basal or “triple 
negative”, “HER2/neu-positive”. These subtypes are 
characterized by different response to the therapy, 
differential course and prognosis of the disease [2–4]. 
Despite wide application of mentioned classification 
in clinical practice, it has series of essential disadvan-
tages, since BC within the limits of even one subtype 
is quite heterogeneous disease both by molecular 
phenotype and clinical course [5, 6]. Last statement 
can be confirmed by results of our previous studies, 
 according to which biomolecular markers which charac-
terize metastatic potential and invasive activity of BC cells 
of certain molecular subtype, have been studied [7].
It is known iron plays an important role in patho-
genesis of many diseases, including cancer [8]. Iron-
containing proteins including heme-containing proteins 
of respiratory chain and ribonucleotide reductase are 
involved in wide range of biological processes: support 
of respiratory function, DNA synthesis, cellular death 
and oxidative stress [8–10]. However, “free” iron pro-
motes the formation of dangerous reactive oxygen spe-
cies (ROS) in cells [11]. Thus, delicate balance between 
useful and harmful action of iron determines survival 
and functioning of cells. One of the proteins, which 
control this balance, is iron-containing protein ferritin.
Ferritin is macromolecular complex, which consists 
of 24 subunits of two types: heavy (H) and light (L) [12]. 
Each organ or tissue, depending on physiological func-
tions, contains certain quantity of H- and L-subunits 
in ferritin [13], and ferritin heavy chain (FTH) content 
is increased in blood serum of BC patients before 
clinical signs of BC. Therefore, FTH determination can 
be used for determination of risk among patients when 
carrying out screening tests [14].
The main function of ferritin is intracellular deposi-
tion of iron (4500 atoms of iron per ferritin molecule) 
in soluble, nontoxic and physiologically available for 
organism form [15–17]. Moreover, H-subunit of ferritin 
acts as peroxidase, i.e. oxidizes iron with formation 
of such side products as ROS, for instance, Н2О2, 
which, as it has been stated above, has extremely 
dangerous consequences for cell [18].
According to the data of literature, cancer deve-
lopment is accompanied with reprogramming of iron 
metabolism in different ways that finally causes ac-
cumulation of iron directly in tumor tissue and cells 
of its microenvironment [14]. In particular, levels 
of iron and ferritin in BC biopsy material are 5–6 times 
higher than in benign tumors. It has been shown that 
ferritin content in blood serum is directly proportional 
to the content of iron and is increased in the cases 
of ovarian, prostate, testicular, pancreatic and he-
patocellular cancer, lymphogranulomatosis, acute 
leukemia, etc. [16]. Also, it has been determined 
that high serum ferritin in BC patients correlates with 
dise ase stage [19]. Our previous in vitro studies have 
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shown that the highest ferritin level and significant 
decrease of microRNA200b expression are observed 
in human BC cells, which are characterized by aggres-
sive mesenchymal phenotype [20]. Thus, the data 
evidence on significance of ferritin for occurrence and 
progression of BC.
The aim of present research was to study pecu-
liarities of disorders of ferritin functioning in BC cells 
of different molecular subtype.
MATERIALS AND METHODS
Cell lines, cell culture and reagents. In the study, 
6 BC cell lines (T47D, MCF-7, MDA-MB-231, MDA-
MB-468, MCF-10A and 184A1) were used.
T47D cells were cultured in RPMI-1640 medium 
(Sigma), supplemented with 0.2 U/ml of bovine insulin 
and 10% fetal bovine serum (FBS). MCF-7 cells were 
cultured in Eagle’s Minimum Essential Medium (Sig-
ma), supplemented with 0.01 mg/ml of human recom-
binant insulin and 10% FBS. MDA-MB-231 and MDA-
MB-468 cells were cultured in Leibovitz’s L-15 medium 
(Sigma), supplemented with 10% FBS. MCF-10A cells 
were cultured in MEBM medium (Lonza), supple-
mented with 100 ng/ml cholera toxin. 184A1 cells were 
cultured in MEBM medium (Lonza), supplemented with 
0.005 mg/ml transferrin and 1 ng/ml cholera toxin. 
Сells were received from the Bank of the Cell Lines 
from Human and Animal Tissues of R.E. Kavetsky 
Institute of Experimental Pathology, Oncology and 
Radiobiology NAS of Ukraine.
Immunocy tochemical assay . The cel ls 
grown up of cover slips were fixed in ice-cold methanol: 
acetone (1:1) at −20 °C for 120 min and incubated with 
1% BSA solution for 20 min. For immunocytochemistry, 
primary monoclonal antibodies аnti-FTH (1:150; anti-
FTH (GTX62020; GeneTex, Irvine, CA, USA)), UltraVi-
sion LP Detection System (Lab Vision, Thermo Scien-
tific) and DAB Quanto (Thermo Scientific) were used 
according to the instructions of the manufacturers. 
When immunocytochemical reaction was completed, 
the cells were stained with hematoxylin by Mayer and 
placed in Faramount Aqueous Mounting Medium (Da-
koCytomation, Denmark). The acquisition of results 
was made by light microscopy (х1000, oil immersion) 
with the use of classical H-Score method: 
S = 1•N1+ + 2•N2+ + 3•N3+, 
where S — “H-Score” index, N1+, N2+ and N3+ — 
number of cells with low, medium or high expression 
of the marker [21]. Low level of studied markers 
expression — from 0 to 100 H-scores, medium le-
vel — from 100 to 200 H-scores and high level — from 
200 to 300 H-scores.
Low-temperature Fe(III) EPR. After 24 h of cul-
turing, the cells were scrapped, washed in PBS, cen-
trifuged at 1000 g for 10 min at 4 ˚C and the pellet was 
re-suspended in PBS. The suspension containing 
2•106 cells was transferred into EPR tubes and im-
mediately frozen in liquid nitrogen. The level of free 
iron was determined by a low-temperature EPR 
method [22]. Briefly, samples were maintained at 
−196 ˚C during recording of the spectra using a finger 
Dewar filled with liquid nitrogen. The following param-
eters were used for the low-temperature EPR: sweep 
width 1525 G; frequency 9.15 GHz; microwave power 
40 mW; modulation amplitude 10.0 G and modulation 
frequency 100 kHz. The g-value was calculated using 
the standard formula: 
g = hv/βH, 
where h — Planck’s constant, v — frequency, 
β — Bohr magneton and H — external magnetic field 
at resonance.
Measurement of intracellular ROS. CM-H2D-
CFDA, a lipid soluble membrane permeable dye upon 
entering cells undergoes deacetylation by intracel-
lular esterases and forms the more hydrophilic, non-
fluorescent dye dichlorodihydrofluorescein (DCFH2). 
This is subsequently oxidized by ROS with formation 
of a highly fluorescent oxidation product, Dichlorofluo-
rescein (DCF). The generated fluorescence is directly 
proportional to the amount of ROS. Fluorescence 
was analyzed by flow cytometry. After centrifugation 
(1500 rpm for 5 min) cells were resuspended in PBS, 
incubated for 30 min at 37 °C with CM-H2DCFDA 
(10 mM) for measurement of ROS. Positive control 
with 25 μM H2O2 was also made (data not presented). 
Cells were masked then and analysed by FC. Fluores-
cence was acquired in the log mode and expressed 
as geometrical mean fluorescence channel (GMean). 
Acquisition was performed on 10,000 gated events.
Measurement of SOD. SOD activity was de-
tected as described earlier [23]. Briefly, cells 
were homo genized in glass homogenizer with 
2 ml of 0.1 М PBS. After centrifugation at 3000 rpm 
for 20 min supernatant was analyzed for SOD activity 
 using radiospectrometer ЕPR-1307 at room tempera-
ture as described in [23].
MicroRNA expression analysis. Total RNA 
extraction from the cells was performed using 
a commercial kit “Rhibo-zol” (Amplisense, Russia) 
as per the manufacturer’s protocol. Concentration 
of isolated RNA was determined using spectro-
photometer “NanoDrop 2000c” (ThermoScientific, 
USA). Purity of isolated RNA is controlled by E260/
E280 ratio. RNA then was dissolved in TE buffer and 
stored at −20 °C. RNA was reverse transcribed to cDNA 
with gene speciﬁc primers according to the TaqMan 
MicroRNA Assay protocol (PE Applied Biosystem) 
using the TaqMan MicroRNA Reverse Transcription 
Kit. Real-time PCR was performed using an Applied 
Biosystems 7500 real-time PCR instrument equipped 
with a 96-well reaction block. The 20 μl PCR mix in-
cluded 5 μl RT product, 10 μl TaqMan Universal PCR 
master mix, and 1 μl of primers from TaqMan MicroRNA 
Assay and was performed for 15 s at 95 °C and 1 min 
at 60 °C for 40 cycles followed by the thermal dena-
turation protocol. The threshold cycle (Ct) was deter-
mined using default threshold settings. The Ct value 
is deﬁned as the fractional cycle number at which 
the ﬂuorescence passesthe ﬁxed threshold. All ex-
periments were done in triplicates and repeated three 
Experimental Oncology 36, 179–183, 2014 (September) 181
times. RNU48 miRNA was used as an internal control 
to normalize RNA input in thereal-time RT-PCR assay. 
The expression of microRNA relative to RNU48 miRNA 
was determined using the 2-ΔCT method.
Statistical analysis. Statistical processing of the 
obtained results was carried out with the help of mathe-
matical program of medical and biological statistics 
STATISTIСA 6.0. Calculation and comparison of the sig-
nificance of differences between the average values 
was carried out with usage of Student’s t-criterion; 
correlation analysis was carried out using the Pearson 
correlation coefficient. Significant were considered 
the differences with the probability not less than 95% 
(р < 0.05).
RESULTS AND DISCUSSION
Immunohistochemical study of FTH expression 
has shown its different expression levels in BC cell 
lines (Table 1). The highest FTH expression (2–3 times 
higher compared with cells of luminal type) has been 
detected in basal subtype cell lines, especially in MDA-
MB 231 and MDA-MB 468 cells. Low and medium FTH 
expression have been observed in cells of luminal 
subtype. Correlation analysis allowed us to determine 
inverse dependence of FTH expression on receptor 
status in basal subtype cells (Table 2).
Table1. Features of expression of FTH, level of “free iron” content, ROS 
and SOD activity in BC cells of different molecular subtype
Cellular lines Molecular subtype
Le vel 
of ex-
pression 
of FTH, 
H-score
Quantity 
of paramag-
netic centers 
of “free iron”, 
spins/ml
Le vel 
of ROS 
generation, 
 G/Mean
SOD 
 activity, 
U/ml
T 47 D Luminal A 94±1.6 0.47±0.1·1016 2.71±0.45 5.8±0.18
MCF-7 Luminal B 125±2.7 0.56±0.1·1016 3.1±0.29 6.9±0.13
MDA-MB 231 Basal subtype 254±2.3 2.9±0.19·1016 11.3±1.05 9.4±0.24
MDA-MB 468 Basal subtype 270±1.9 3.0±0.22·1016 7.27 ±0.26 8.5±0.18
MCF-10 A Basal subtype 223±1.8 1.0±0.3·1016 3.9±0.15 6.5±0.31
184 A 1 Basal subtype 206±1.9 1.4±0.35·1016 4.94±0.22 7.3±0.11
Table 2. Coefficients of correlation between expression of FTH and other 
studied indexes of BC cells of different molecular subtypes
Indexes Value of correlation coefficientLuminal type Basal type
FTH/ER −0.12 −0.46*
FTH/PR −0.13 −0.44*
FTH/Ki-67 0.51* 0.25*
FTH/colony formation 0.12 0.09
FTH/number of paramagnetic centers of “free iron” 0.44* 0.39*
FTH/level of ROS generation 0.32* 0.22*
FTH/activity of SOD 0.36 * 0.14*
FTH/colony formation 0.12 0.09
FTH/number of paramagnetic centers of “free iron” 0.44* 0.39*
FTH/activity of SOD 0.36* 0.14*
Notes: ER — estrogen receptor; PR — progesterone receptor; *р < 0.05.
Since we have demonstrated in previous studies that 
cells of luminal and basal subtypes of BC are essentially 
different by tumorigenic properties in vitro, and their 
proliferative activity varies within wide limits, we have 
compared FTH expression and these in dexes [7]. It has 
been determined that level of FTH expression correlates 
with proliferative activity of BC cells of both luminal (r = 
0.51) and basal (r = 0.25) subtypes. It has been dem-
onstrated that level of FTH expression does not corre-
lated with tumorigenic activity of cells of both studied 
subtypes (Table 2). Thus, we have determined that cells 
of luminal and basal BC are essentially different by FTH 
expression, which within the limits of particular subtypes 
is associated with cell proliferative activity.
It is known that the main function of ferritin 
is deposition of iron ions, i.e. its expression level cor-
relates with content of “free iron” in tumor cells [6, 
7]. Indeed, the highest “free iron” content among 
studied BC cell lines has been observed in basal 
molecular subtype cell lines MDA-MB 231and MDA-
MB468 and constituted 2.9 ± 0.19•1016 spins/ml and 
3.0±0.22•1016 spins/ml, respectively. We emphasize 
that these cells are characterized with highest FTH 
expression, lack of steroid hormone receptors, high 
proliferative potential and tumorigenicity.
In cells of T47D and MCF-7 lines, luminal 
A and B molecular subtypes, content of “free iron” 
was reliably lo wer — 0.47 ± 0.1•1016 spins/ml and 
0.56 ± 0.1•1016 spins/ml, respectively (p  < 0.05). When 
analyzing features of cells of basal molecular subtype 
MCF-10 A and 180A1, it should be mentioned that for 
these cells mode rate proliferative activity and, along 
with it, medium FTH expression, insignificant content of 
“free iron” and high colony forming are typical. Analysis 
of dependencies of FTH expression on content of free 
iron allowed us to determine correlation of these indexes 
in cells of both studied subtypes (Table 2).
Next, we have compared ROS and SOD indexes 
as integral representation of the “free iron” level 
in BC cells of different molecular subtypes. As it is shown 
in Table 1, in cells luminal A (T47D) and B (MCF-7) mo-
lecular subtypes, the lowest le vels of ROS generation 
and SOD activity has been observed. ROS content and 
SOD activity in cells of luminal subtype was associated 
with low expression of FTH, content of “free iron” and 
proliferative activity of cells (Table 2).
In BC cells of basal subtype, medium and high 
levels of ROS and SOD activity have been detected 
(Table 1). The highest indexes of ROS and SOD, which 
were associated with high “free iron” content, FTH 
expression, proliferative activity of cells have been 
determined in MDA-MB 231 and MDA-MB 468 cells 
of basal molecular subtype (Table 2).
Thus, we have determined that there is a relation 
between FTH expression, content of free iron, ROS 
and SOD in BC cells of different molecular subtype.
It is known that BC malignancy grade is accom-
panied with certain epigenоmic changes in tumor 
cells [3]. For evaluation of role of epigenomic com-
ponent in determination of FTH expression in cells 
of studied lines, we have analyzed features of mi-
croRNA expression, which participates in regulation 
of expression of this protein. Since in previous studies 
we have shown that miR-200b plays important role 
in post-transcriptional regulation of ferritin expression 
(FTH is a target of miR-200b) [20], we have focus our 
attention on study of miR-200b expression. As one may 
see in the Figure, the highest level of miR-200b ex-
pression has been observed in T47D and MCF-7 cells 
of luminal subtype. In 184A1 and MCF10A cells 
of basal subtype, microRNA 200b expression level 
reliably decreased compared with control and cells 
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of luminal subtype. The lowest indexes of microRNA 
200b expression have been determined in BC cells 
of basal subtype (MDA-MB-231 and MDA-MB-468). 
The obtained data demonstrate that there is a depen-
dence between FTH expression and microRNA, which 
participates in regulation of this protein.
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Figure. MicroRNA 200b expression in BC cells of different 
molecular subtype
So, our data show that there are certain correla-
tions between FTH expression and such indexes 
of BC malignancy as proliferation rate, receptor status 
and colony forming activity (Table 2). In particular, 
FTH expression directly correlates with proliferative 
activity of BC cells of both luminal and basal subtypes, 
inversely correlates with expression of steroid hor-
mones in cells of basal subtype and does not depend 
on tumorigenic activity of both subtypes. The cells 
of luminal subtype B of MCF-7 line and basal subtype 
of MDA-MB-231 and MDA-MB-468 lines with high 
proliferative activity contain the highest level of free 
iron that can be consequence of intensive use of this 
element by cells, which actively divide and grow. 
In basal subtype MDA-MB-231 and MDA-MB-468 cell 
lines, high levels of FTH, ROS and SOD are detected, 
as well as decreased expression of microRNA 200b. 
In contrast, cells of luminal subtype B MCF-7 line were 
distinguished by high expression of microRNA 200b 
and low ferritin level, what evidences that certain 
molecular subtypes of BC are characterized by dif-
ferences in regulatory mechanisms of storage and 
accumulation of endogenous iron.
Moreover, among four studied lines of basal sub-
types, two subtypes can be distinguished by determined 
indexes: 1) cells of MDA-MB 231 and  MDA-MB 468 lines 
are characterized by high proliferative activity and 
tumorigenicity in vitro, high level of FTH expres-
sion, content of “free iron”, ROS and SOD; 2) cells 
of  MCF-10 A and 184A1 lines are characterized 
by moderate proliferative activity and tumorigenicity, 
medium content of FTH, high content of “free iron”, 
moderate levels of ROS and SOD activity.
The role of iron metabolism in tumor develop-
ment is one of the fundamental problems of modern 
experimental oncology [8, 10, 24]. Such studies are 
of special interest in the context of BC, since hormonal 
status of woman is tightly associated with significant 
shifts of iron content in organism. Both deficiency and 
proficiency of iron can have negative consequences 
for health. It is known that in developed countries, 20% 
of women have iron deficiency that is an additional 
factor, which causes increase of VEGF concentration 
and, as the result, activation of angiogenesis in women 
of premenopausal period [25]. Also, there is a syner-
gism of iron and estrogen metabolism disorders 
in BC occurrence [26–28]. In the process of malignant 
transformation the excess of iron contributes to ROS 
formation causing DNA damage. At the same time, 
estrogen can act as additional substrate in these reac-
tions due to adjunction of hydroxyl group and forma-
tion of catechol estrogen, which is one of the factors 
of hormonal carcinogenesis.
We have analyzed certain mechanisms involved 
in iron metabolism in BC cells of different molecular 
subtypes. Our data demonstrate that BC cells, which 
are referred to different molecular subtypes, are cha-
racterized by shifts in intercellular iron balance asso-
ciated of altered indexes mentioned above. Obtained 
data are in accordance with the results of our previ-
ous studies concerning significant increase of FTH 
in BC cells of aggressive mesenchymal subtype and 
in BC cells with phenotype of drug resistance to cispla-
tin and doxorubicin [20, 30–31]. So, disorders of FTH 
expression may reflect biological properties of luminal 
and basal BC subtypes and play a role in clinical course 
of breast cancer BC.
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